Use of genetically engineered mice as models for exploring the role of oxidative stress in neurodegenerative diseases.

A growing body of evidence has suggested that oxidative stress may play a major role in the degeneration of neurons associated with several neurological diseases of aging including ALS, Parkinson's, and Alzheimer's disease; this has been the topic of numerous previous reviews and opinion papers (e.g. 1-10). The ability to construct genetically engineered mouse lines containing targeted mutations has done much to aid in the assessment of the role of reactive oxygen species (ROS) in both the initiation as well as the progression of these diseases and has markedly advanced research in the field. Most importantly, the creation of genetic animal models has strengthened the argument that antioxidants may be a useful therapy in the treatment of these types of disorders.

[1]  P. Jenner,et al.  Oxidative stress in Parkinson's disease and other neurodegenerative disorders. , 1996, Pathologie-biologie.

[2]  D. Butterfield,et al.  Direct evidence of oxidative injury produced by the Alzheimer's β-Amyloid peptide (1–40) in cultured hippocampal neurons , 1995, Experimental Neurology.

[3]  S. Harik,et al.  Strain differences in systematic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity in mice correlate best with monoamine oxidase activity at the blood-brain barrier , 1988 .

[4]  R. Palmiter,et al.  Transgenic mice , 1985, Cell.

[5]  Graybiel Am.  The basal ganglia and the initiation of movement. , 1990 .

[6]  D. Bredesen,et al.  Altered Reactivity of Superoxide Dismutase in Familial Amyotrophic Lateral Sclerosis , 1996, Science.

[7]  E. Stadtman,et al.  A gain-of-function of an amyotrophic lateral sclerosis-associated Cu,Zn-superoxide dismutase mutant: An enhancement of free radical formation due to a decrease in Km for hydrogen peroxide. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[8]  M. Beal,et al.  Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury , 1996, Nature Genetics.

[9]  D. Borchelt,et al.  Superoxide dismutase 1 with mutations linked to familial amyotrophic lateral sclerosis possesses significant activity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[10]  D. Borchelt,et al.  An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria , 1995, Neuron.

[11]  M. Carson,et al.  ALS, SOD and peroxynitrite , 1993, Nature.

[12]  P. Sonsalla,et al.  Correlation between the neostriatal content of the 1-methyl-4-phenylpyridinium species and dopaminergic neurotoxicity following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to several strains of mice. , 1991, The Journal of pharmacology and experimental therapeutics.

[13]  L. R. Williams.  Oxidative stress, age-related neurodegeneration, and the potential for neurotrophic treatment. , 1995, Cerebrovascular and brain metabolism reviews.

[14]  Joseph B. Martin,et al.  Differential sparing of somatostatin‐neuropeptide y and cholinergic neurons following striatal excitotoxin lesions , 1989, Synapse.

[15]  M. Gurney,et al.  Transgenic mice carrying a human mutant superoxide dismutase transgene develop neuronal cytoskeletal pathology resembling human amyotrophic lateral sclerosis lesions. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[16]  E. Hirsch.  Why are nigral catecholaminergic neurons more vulnerable than other cells in Parkinson's disease? , 1992, Annals of neurology.

[17]  P. Jenner.  Oxidative stress as a cause of Parkinson's disease , 1991, Acta neurologica Scandinavica. Supplementum.

[18]  R. Swingler,et al.  Identification of a novel SOD1 mutation in an apparently sporadic amyotrophic lateral sclerosis patient and the detection of Ile113Thr in three others. , 1994, Human molecular genetics.

[19]  T. Dawson,et al.  Nitric oxide synthase in models of focal ischemia. , 1997, Stroke.

[20]  P. Andersen,et al.  Amyotrophic lateral sclerosis associated with homozygosity for an Asp90Ala mutation in CuZn-superoxide dismutase , 1995, Nature Genetics.

[21]  M. Gurney,et al.  Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. , 1994, Science.

[22]  R. Albin,et al.  Alternative excitotoxic hypotheses , 1992, Neurology.

[23]  Y. Suh,et al.  Ionic effects of the Alzheimer's disease β-amyloid precursor protein and its metabolic fragments , 1997, Trends in Neurosciences.

[24]  A. Graybiel,et al.  The nigrostriatal system in Parkinson's disease. , 1990, Advances in neurology.

[25]  D. Calne,et al.  AETIOLOGY OF PARKINSON'S DISEASE , 1983, The Lancet.

[26]  J. Morrison,et al.  Transgenic mice expressing an altered murine superoxide dismutase gene provide an animal model of amyotrophic lateral sclerosis. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[27]  L. Mucke,et al.  Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein , 1995, Nature.

[28]  M. Beal,et al.  Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? , 1992, Annals of neurology.

[29]  J. Richardson,et al.  Determination and analysis of the 2 A-structure of copper, zinc superoxide dismutase. , 1980, Journal of molecular biology.

[30]  J. Gusella,et al.  Molecular genetics of Huntington's disease. , 1993, Archives of neurology.

[31]  M. Hayden,et al.  Of molecular interactions, mice and mechanisms: new insights into Huntington's disease. , 1997, Current opinion in neurology.

[32]  C. Epstein,et al.  3‐Nitropropionic Acid Neurotoxicity Is Attenuated in Copper/Zinc Superoxide Dismutase Transgenic Mice , 1995, Journal of neurochemistry.

[33]  J. Julien,et al.  Defective axonal transport in a transgenic mouse model of amyotrophic lateral sclerosis , 1995, Nature.

[34]  M. Gurney,et al.  Oxidative stress, mutant SOD1, and neurofilament pathology in transgenic mouse models of human motor neuron disease. , 1997, Laboratory investigation; a journal of technical methods and pathology.

[35]  Charles J. Epstein,et al.  Overexpressing Cu/Zn superoxide dismutase enhances survival of transplanted neurons in a rat model of Parkinson's disease , 1995, Nature Medicine.

[36]  Zhang Ming,et al.  Bioenergetic and Oxidative Stress in Neurodegenerative Diseases , 2000 .

[37]  W. Ying.  A new hypothesis of neurodegenerative diseases: the deleterious network hypothesis. , 1996, Medical hypotheses.

[38]  J. Shih,et al.  Increased stress response and beta-phenylethylamine in MAOB-deficient mice. , 1997, Nature genetics.

[39]  J W Langston,et al.  MPTP: current concepts and controversies. , 1986, Clinical neuropharmacology.

[40]  John B Davis.  Oxidative Mechanisms in β-Amyloid Cytotoxicity , 1996 .

[41]  D. Selkoe.  The molecular pathology of Alzheimer's disease , 1991, Neuron.

[42]  C. Marsden,et al.  Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia , 1994, Annals of neurology.

[43]  R. Palmiter,et al.  Peripheral neuropathies, hepatocellular carcinomas and islet cell adenomas in transgenic mice , 1985, Nature.

[44]  D. D. Di Monte,et al.  Glutathione in Parkinson's disease: A link between oxidative stress and mitochondrial damage? , 1992, Annals of neurology.

[45]  J. Hardy,et al.  New insights into the genetics of Alzheimer's disease. , 1996, Annals of medicine.

[46]  M. Capecchi.  The new mouse genetics: altering the genome by gene targeting. , 1989, Trends in genetics : TIG.

[47]  Takeshi Kumazawa,et al.  Increased stress response and β–phenylethylamine in MAOB–deficient mice , 1997, Nature Genetics.

[48]  R. Rydel,et al.  Amyloid β‐Mediated Oxidative and Metabolic Stress in Rat Cortical Neurons: No Direct Evidence for a Role for H2O2 Generation , 1996, Journal of neurochemistry.

[49]  C. Epstein,et al.  Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[50]  Olanow Cw,et al.  Metals and free radicals in neurodegeneration. , 1994 .

[51]  V. Meininger,et al.  Variants of the heavy neurofilament subunit are associated with the development of amyotrophic lateral sclerosis. , 1994, Human molecular genetics.

[52]  F. Crawford,et al.  Genetic and molecular advances in Alzheimer's disease. , 1993, Trends in neurosciences.

[53]  M. Beal.  Mitochondria, free radicals, and neurodegeneration , 1996, Current Opinion in Neurobiology.

[54]  Joseph B. Martin,et al.  Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid , 1986, Nature.

[55]  M. Mullan,et al.  Genetics and molecular advances in Alzheimer's disease , 1993, Trends in Neurosciences.

[56]  B. Rosen,et al.  Age‐Dependent Vulnerability of the Striatum to the Mitochondrial Toxin 3‐Nitropropionic Acid , 1993, Journal of neurochemistry.

[57]  M. Capecchi,et al.  Altering the genome by homologous recombination. , 1989, Science.

[58]  L. Packer,et al.  Oxidative stress and mitochondrial dysfunction in neurodegeneration. , 1994, Biochemistry and molecular biology international.

[59]  A. Joyner,et al.  Inactivation of the mouse Huntington's disease gene homolog Hdh. , 1995, Science.

[60]  S. Floresco,et al.  Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes , 1995, Cell.

[61]  Williams Lr.  Oxidative stress, age-related neurodegeneration, and the potential for neurotrophic treatment. , 1995 .

[62]  G. Cohen.  Monoamine oxidase, hydrogen peroxide, and Parkinson's disease. , 1987, Advances in neurology.

[63]  J. Julien,et al.  Progressive neuronopathy in transgenic mice expressing the human neurofilament heavy gene: A mouse model of amyotrophic lateral sclerosis , 1993, Cell.

[64]  J. Cadet.  Free radicals and neurodegeneration , 1994, Trends in Neurosciences.

[65]  F. Gage,et al.  Radical directions in Parkinson's disease , 1995, Nature Medicine.

[66]  I. Fridovich,et al.  Intracellular production of superoxide radical and of hydrogen peroxide by redox active compounds. , 1979, Archives of biochemistry and biophysics.

[67]  J. Andersen,et al.  Effect of Buthionine Sulfoximine, a Synthesis Inhibitor of the Antioxidant Glutathione, on the Murine Nigrostriatal Neurons , 1996, Journal of neurochemistry.

[68]  S. Younkin,et al.  Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice , 1996, Science.

[69]  J. Haines,et al.  Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis , 1993, Nature.

[70]  J. Langston,et al.  The etiology of Parkinson's disease with emphasis on the MPTP story , 1996, Neurology.

[71]  J. Davis.  Oxidative mechanisms in beta-amyloid cytotoxicity. , 1996, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.

[72]  J. Coyle,et al.  Oxidative stress, glutamate, and neurodegenerative disorders. , 1993, Science.

[73]  M. Mattson,et al.  A Role for 4‐Hydroxynonenal, an Aldehydic Product of Lipid Peroxidation, in Disruption of Ion Homeostasis and Neuronal Death Induced by Amyloid β‐Peptide , 1997, Journal of neurochemistry.

[74]  M. Baudry,et al.  beta-Amyloid toxicity in organotypic hippocampal cultures: protection by EUK-8, a synthetic catalytic free radical scavenger. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[75]  J. Andersen,et al.  Genetic elevation of monoamine oxidase levels in dopaminergic PC12 cells results in increased free radical damage and sensitivity to MPTP , 1996, Journal of neuroscience research.

[76]  D. Price,et al.  Elevated free nitrotyrosine levels, but not protein-bound nitrotyrosine or hydroxyl radicals, throughout amyotrophic lateral sclerosis (ALS)-like disease implicate tyrosine nitration as an aberrant in vivo property of one familial ALS-linked superoxide dismutase 1 mutant. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[77]  M. Beal,et al.  Aging, energy, and oxidative stress in neurodegenerative diseases , 1995, Annals of neurology.

[78]  S. W. Davies,et al.  Exon 1 of the HD Gene with an Expanded CAG Repeat Is Sufficient to Cause a Progressive Neurological Phenotype in Transgenic Mice , 1996, Cell.

[79]  A. Graybiel.  The basal ganglia and the initiation of movement. , 1990, Revue neurologique.

[80]  M. Mattson,et al.  Amyloid beta-peptide impairs ion-motive ATPase activities: evidence for a role in loss of neuronal Ca2+ homeostasis and cell death , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[81]  R. Bronson,et al.  Mice Deficient in Cellular Glutathione Peroxidase Develop Normally and Show No Increased Sensitivity to Hyperoxia* , 1997, The Journal of Biological Chemistry.

[82]  C J Epstein,et al.  Transgenic Murine Dopaminergic Neurons Expressing Human Cu/Zn Superoxide Dismutase Exhibit Increased Density in Culture, but No Resistance to Methylphenylpyridinium‐Induced Degeneration , 1997, Journal of neurochemistry.

[83]  Robert H. Brown,et al.  Amyotrophic lateral sclerosis: Recent insights from genetics and transgenic mice , 1995, Cell.